Engflag

Berlipril 10

Quick links to important sections

Berlipril 10

Selected form

Berlipril 10_EN

Method of action: Ace Inhibiting, Agents Acting In The Renin-Angiotensin System, Antihypertensive, Hypotensive, Vasoconstrictive, Vasodilator

Treatment option: Hypertensive Renal Disease, Hypertension, Left Ventricular Dysfunction, Heart Failure

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Berlipril 10

Property Description
Active ingredient Enalapril maleate
Form Tablet (Oral)
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
General Purpose Reduction of peripheral vascular resistance
Origin Synthetic (Prodrug)

Berlipril 10 is a specific formulation of the prescription-only medicine enalapril maleate, classified as a synthetic Angiotensin-Converting Enzyme (ACE) inhibitor designed to help manage cardiovascular function. Administered via the oral route, this single-ingredient product is defined by its 10 mg strength of the active substance, a mid-range concentration often used for patients initiating or maintaining therapy. Its long-acting nature distinguishes it from some older members of the ACE inhibitor class, requiring less frequent dosing.

What Type of Medicine is Berlipril 10?

Berlipril 10 is fundamentally an antihypertensive agent belonging to the ACE inhibitor class. Its key component, enalapril maleate, is a synthetic compound that functions as a prodrug. This means the orally ingested compound is inactive until it is converted by the liver into its therapeutic form, enalaprilat. This particular drug is chemically recognized as a nonsulphydryl antihypertensive agent, a structural feature that offers therapeutic differentiation compared to earlier ACE inhibitors. It is clinically recognized for its efficacy in relaxing blood vessels and easing the heart's workload, which is the primary benefit of this therapeutic class.

Composition and Form: Understanding the Enalapril Tablet

The preparation is provided as a tablet for convenient oral administration. The numerical designation 10 specifically indicates that each tablet contains 10 mg of the active substance, enalapril maleate. The tablet is composed of the active component along with solid pharmaceutical excipients that ensure proper delivery and systemic absorption. This formulation of enalapril is recognized as an essential medicine, a status that underscores its importance in foundational healthcare systems globally.

General Purpose and High-Level Physiological Effect

The general purpose of this medication is to reduce systemic peripheral vascular resistance through targeted vasodilation. Its physiological effect stems from the Inhibition of ACE, which suppresses the activity of the Renin-Angiotensin-Aldosterone System (RAAS), a primary pathway for regulating vascular tension and fluid balance. By inhibiting the formation of potent constrictors, the drug promotes the relaxation of blood vessel walls, which lessens the total force against which the heart must pump blood. The therapeutic role of ACE inhibitors in reducing long-term cardiovascular risk is a recognized clinical outcome that validates the use of this mechanism for patients requiring cardiovascular support.

What side effects are possible with Berlipril 10?

Official Safety Profile of Berlipril 10 (Enalapril Maleate)

Official regulatory documents classify the potential effects of enalapril maleate by their documented frequency and the affected body system. This framework defines both expected and serious adverse reactions.

Frequency-Classified Adverse Reactions

Adverse effects are grouped into standard regulatory frequency categories:

  • Very Common: These effects are documented to occur in 1 out of 10 people or more. Examples include dry cough and blurred vision.
  • Common: Occurring in less than 1 in 10 but more than 1 in 100 people. Examples include headache, dizziness, fatigue, and hypotension (low blood pressure).
  • Uncommon / Rare: These categories include less frequently observed effects such as anaemia, confusion, pancreatitis, and severe blood or marrow disorders like agranulocytosis. Hepatic failure and acute renal failure are documented as serious, rare possibilities.

Serious Adverse Reactions and Key Constraints

The most significant safety constraint is angioedema, a rapid swelling of the face, lips, tongue, or larynx, which can be potentially fatal. This reaction can occur at any time but is often observed during the first weeks of treatment. Individuals with a history of angioedema related to previous ACE-inhibitor therapy are formally contraindicated from using this medicine. Excessive drops in blood pressure (symptomatic hypotension) are more likely to occur following the initial dose, particularly in volume-depleted patients.

Population-Specific Safety Notes

The medicine is strictly contraindicated during the second and third trimesters of pregnancy due to the potential for fetal injury and death. Safety documents also highlight that symptomatic hypotension is more likely in patients with severe heart failure or those with renal impairment, requiring specific attention in these patient populations.

Overdose and Emergency Response

Overdose: When to Seek Help (Official Regulatory Information)

This information describes the documented overdose profile of Berlipril 10 (Enalapril), based strictly on authoritative government regulatory sources.

Documented Overdose Manifestations and Severity

The most likely and primary clinical manifestation of Enalapril overdose is marked hypotension (excessive low blood pressure), often accompanied by lightheadedness or fainting (syncope). Severe, life-threatening outcomes documented in regulatory texts include progression to circulatory shock, stupor (unresponsiveness), and disturbances in heart rate such as tachycardia (rapid heart rate) or bradycardia. Acute renal failure is a potential severe outcome.

Emergency Actions and Management

Immediate medical help is required in all cases of suspected overdose. Seek emergency services immediately if the individual has collapsed, is experiencing trouble breathing, or cannot be awakened.

Management, as described in official documents, is symptomatic and supportive. This involves placing the patient in a supine position and administering intravenous fluids to restore volume and blood pressure. Enalaprilat is dialyzable, meaning hemodialysis can be considered in severe cases, especially in patients with existing renal impairment.

Observation and Monitoring: Asymptomatic individuals require monitoring for a minimum of four hours. Patients who remain symptomatic or hypotensive require hospital admission for observation for at least 24 hours.

Therapeutic Uses of Berlipril 10

What Berlipril 10 Treats: Main Uses and Benefits

Berlipril 10 (Enalapril maleate) is generally applied across therapeutic domains that involve systemic imbalance and organ-specific functional stress, contributing to long-term cardiovascular support. It is considered relevant for managing chronic hypertension and addressing symptomatic heart failure.

Key Therapeutic Applications

This medication is commonly used across conditions characterized by high blood pressure, which often creates noticeable physiological strain on the body, as well as for symptomatic heart failure and reduced cardiac function. It is also applied in high-risk patients with co-existing conditions, such as diabetes, where additional support for organ function is needed.

The treatment helps address symptom clusters related to physical discomfort and functional stability, such as exertional fatigue and shortness of breath. The use of this drug assists with maintaining functional stability and supports general well-being during symptomatic phases linked to long-term chronic illness.

Quick Fact

Quick Fact: Support for Symptoms that Interfere with Daily Functioning

This medicine is relevant for easing symptoms like shortness of breath and fatigue that interfere with daily functioning, providing supportive relief when symptoms interfere with routine activities.

Summary of Benefits

By managing elevated vascular pressure, Berlipril 10 provides support that helps ease the overall symptom burden. In heart failure contexts, it assists with maintaining functional stability and supports patients during episodes of heightened discomfort.

Regulatory References

  1. NIH DailyMed label for Enalapril maleate

Eligibility and Restrictions for Use

Berlipril 10 (enalapril maleate) is subject to specific regulatory rules defining which patient populations are eligible for its use. This section details the official criteria regarding who is permitted, restricted, or prohibited from using the medicine.

Official Eligibility Status

Population Category Regulatory Classification
Approved Age Groups Adults; Children ge 1 month of age (for hypertension).
Must Not Use (Contraindicated) History of angioedema related to any ACE inhibitor; hereditary or idiopathic angioedema; second and third trimesters of pregnancy.
Specific Drug Prohibitions Patients taking sacubitril/valsartan (prohibited within 36 hours); patients with diabetes or renal impairment (GFR < 60 mL/min/1.73 m^2) taking aliskiren-containing products.

Restrictions and Conditional Use

Use is not recommended in infants under one month of age and in pediatric patients with severe renal impairment (GFR < 30 mL/min/1.73 m^2). The drug is not recommended for use during the first trimester of pregnancy or while breastfeeding. Patients with underlying conditions such as aortic stenosis or renal artery stenosis may require use under close supervision, as specified in regulatory labeling.

What should I know about interactions with other medicines?

The active substance in Berlipril 10 (Enalapril) is an Angiotensin-Converting Enzyme (ACE) inhibitor, and its official interaction profile details several restricted or contraindicated combinations, primarily concerning the risk of severe blood pressure drops, high potassium levels, and kidney impairment.

Contraindicated and Highly Restricted Combinations

  • The use of Enalapril with Sacubitril/Valsartan (a Neprilysin inhibitor/Angiotensin Receptor Blocker combination) is contraindicated due to a significantly increased risk of angioedema (serious swelling). A mandatory 36-hour wash-out period is required when switching between these agents.
  • Co-administration with Aliskiren (a Direct Renin Inhibitor) is contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment.
  • Dual blockade of the Renin-Angiotensin System (RAAS) by combining Enalapril with an Angiotensin II Receptor Blocker (ARB) or Aliskiren is generally not recommended due to increased risks of kidney problems, hyperkalemia, and hypotension.

Interactions Requiring Close Monitoring

  • Medicines that increase serum potassium (e.g., potassium-sparing diuretics, potassium supplements, trimethoprim) should be used with caution, as Enalapril increases the risk of hyperkalemia.
  • The use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, may reduce the blood pressure-lowering effect and increase the risk of deterioration in renal function.
  • Lithium clearance is reduced by Enalapril, requiring frequent monitoring of serum lithium levels to prevent toxicity.
  • Concomitant use with other antihypertensive agents, including diuretics, may result in a greater blood pressure reduction (hypotension).

Mechanism of Action

Berlipril 10 contains enalapril maleate, a pharmacologically inactive prodrug. Following absorption, enalapril undergoes rapid hepatic hydrolysis to form its active metabolite, enalaprilat. The core action of enalaprilat is the competitive inhibition of the Angiotensin-Converting Enzyme (ACE), a crucial component of the Renin-Angiotensin-Aldosterone System (RAAS). Enalaprilat binds to the active site of ACE, preventing its enzymatic function. This enzyme inhibition blocks the conversion of angiotensin I into angiotensin II. Angiotensin II is a potent endogenous vasoconstrictor and a stimulator of aldosterone secretion. Consequently, the reduced systemic concentration of angiotensin II modulates the activity of the RAAS. This mechanistic cascade results in generalized vasodilation (widening of peripheral blood vessels) and decreased synthesis and release of aldosterone. The physiological consequence of these combined actions is a net decrease in total peripheral vascular resistance and an alteration of fluid volume dynamics within the circulatory system.

Dosage and Administration Information

Official Administration Guidelines

Berlipril 10 (enalapril maleate) is an oral medication taken as a tablet or, for certain patients, an oral solution. The use of this drug is structured by specific official dosing rules and procedural steps outlined in regulatory documents.

Administration Scope Official Instruction
Route of Administration Oral. Tablets must be swallowed whole with water.
Timing in Relation to Meals May be taken with or without food, as absorption is generally unaffected.
Standard Dosing Schedule Initial adult dose for hypertension is typically 5 mg once daily, titrating up to a maintenance dose of 10 mg or 20 mg once daily, not to exceed 40 mg daily. For heart failure, the initial dose is lower, typically 2.5 mg once or twice daily, titrated gradually.
Frequency Pattern Usually administered once daily. Dosing may be divided into two times daily if the therapeutic effect diminishes toward the end of the 24-hour interval.
Dose Adjustment Rules A lower starting dose of 2.5 mg is required for patients with renal impairment (Creatinine Clearance ≤ 30 mL/min) and for patients currently taking diuretics.
Missed Dose Rule If a dose is missed, take it as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped; a double dose should not be taken to compensate.

Official Procedural Structure

Treatment initiation is procedural and involves taking the prescribed dose orally at the same time(s) each day. The first step involves starting with a low dose, which is then gradually and carefully increased (titrated) over days or weeks, as directed by a healthcare professional, to reach the optimal maintenance dose. Dosage adjustments are mandatory when administration occurs in specific populations, such as in the presence of kidney dysfunction, to align with regulatory safety profiles.

Recent Clinical Evidence

Research evidence / Overview of Studies for Berlipril 10

Evidence for Use in Chronic Hypertension (High Blood Pressure)

The research base for Chronic Hypertension is built upon large-scale Randomized Controlled Trials (RCTs). These studies compared the medicine against placebo or other established treatments, monitoring and measuring changes in both systolic and diastolic blood pressure readings over time. These studies also tracked the occurrence of major cardiovascular events to understand long-term patterns.

Studies report measurements of changes in blood pressure readings in the observed populations. Findings describe patterns observed in studies spanning short periods (e.g., eight weeks for initial response) up to several years for evaluating effects. However, data show patterns related to how blood pressure responds that vary across different racial groups when the medicine is used alone. The evidence remains limited in fully characterizing how the findings from these studies relate to those of research involving newly developed antihypertensive drug classes.

Evidence for Use in Symptomatic Heart Failure

The research base for symptomatic heart failure relies on several landmark, long-term, placebo-controlled RCTs conducted in adults experiencing different degrees of heart failure symptoms (NYHA Class II-IV). These studies explored outcomes related to functional stability and physiological strain. Researchers monitored several key clinical endpoints, including all-cause and cardiovascular death and the frequency of hospitalization related to heart failure.

Findings describe patterns observed in the studies regarding long-term mortality in the groups receiving the medicine compared to control groups over periods extending past four years. Research describes changes measured during the study period concerning patient-reported symptoms, such as shortness of breath and fatigue. Data for long-term outcomes in very specific subgroups, such as the frail elderly or those with advanced, concurrent kidney disease, remain insufficient.

Evidence in Special Populations (Children and Specific Subgroups)

Research examining enalapril maleate in children and adolescents with high blood pressure involves smaller-scale RCTs and studies focused on pharmacokinetics (how the body handles the drug). These studies explored short-term symptom changes, primarily measuring dose-dependent changes in blood pressure. Research also describes the amount needed to achieve levels in children that are consistent with levels observed in the adult studies.

Follow-up durations were limited in the pediatric studies, and sample sizes were modest compared to adult trials. Data for certain groups remain insufficient, specifically for children under the age of one month and for children who have severe kidney impairment. Studies help show what has been observed so far, but the research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Berlipril 10 (FAQ)

Q: How long after starting Berlipril 10 can I expect my blood pressure to start going down?

A: Official information suggests a blood pressure reduction can begin within a few hours after taking the first dose. However, the full or maximal effect of the medicine, which is the complete lowering of blood pressure, may take several weeks of continuous treatment to fully develop.

Q: What should I do if I accidentally take two doses of Berlipril 10 at once?

A: Taking more than the prescribed amount is considered an overdose, which can cause symptoms such as severe dizziness, lightheadedness, or a pounding heartbeat. An overdose requires immediate contact with a poison control center or emergency medical services.

Q: What is the specific maximum daily dose of Berlipril 10 for treating symptomatic heart failure?

A: Regulatory labeling states that the maximum daily amount established for heart failure is 40 mg. This total amount is typically administered in two divided doses. Final dosing decisions are always determined by a prescribing healthcare professional.

Q: Will Berlipril 10 help my shortness of breath and fatigue if I have heart failure?

A: Studies indicate that this medicine is used to manage heart failure and its associated symptoms. By working to improve cardiovascular function, it is generally used to reduce the signs of heart failure, which can include both shortness of breath and fatigue.

Q: What are the symptoms of hypotension (low blood pressure) that I should look out for?

A: Low blood pressure, or hypotension, is a commonly reported side effect, particularly when treatment begins. Official drug safety documents advise patients to watch for common symptoms like feeling faint or lightheaded, general dizziness, or blurred vision.

Q: Is it okay to crush or chew the Berlipril 10 tablet instead of swallowing it whole?

A: Official administration guidelines generally state that the tablets should be swallowed whole with water. While some regulatory patient information notes that if you have difficulty swallowing, the tablet may sometimes be broken or crushed, consultation with a healthcare professional is recommended before changing how the tablet is taken.

Q: How should I store Berlipril 10 when traveling in my car during the summer?

A: The tablets must be stored at a controlled room temperature, typically between 20 C and 25 C, and protected from moisture. Official guidance emphasizes that the product should be protected from high temperatures, such as those that can build up inside a hot car cabin, to maintain its stability.

How should Berlipril 10 be stored and disposed of?

Storage and Disposal of Berlipril 10 (Enalapril Maleate)

Storage and disposal requirements for Berlipril 10 tablets are defined by regulatory bodies to maintain the product's quality and ensure public safety.

Storage/Disposal Component Official Regulatory Requirement
Temperature Store at controlled room temperature (mathbf20 C to mathbf25 C), with temporary excursions permitted between mathbf15 C and mathbf30 C. Some labels state: Do not store above 25 C (or 30 C).
Container & Protection Keep the product in the original container and ensure the container is tightly closed. The tablets must be protected from moisture.
Child Safety The medicine must be kept out of the reach of children for accidental ingestion prevention.
Disposal Disposal of unused or expired tablets should be managed by asking a healthcare professional or pharmacist. Patients are instructed to follow local regulations or use a medication take-back program.

These official statements dictate that the tablets must be stored in a dry, cool location within the prescribed temperature range to preserve stability. Final disposition must adhere to authorized pharmaceutical waste procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagRussia

Equivalent of Berlipril 10 found in:

A-Z Index: